Abstract: Methods are provided herein for determining the likelihood that a subject, such as an asymptomatic subject, has chlamydial pelvic inflammatory disease. In some embodiments, the method can determine the likelihood that a pharmaceutical agent is effective for treating a subject that has chlamydial pelvic inflammatory disease. In other specific non-limiting examples, the method predicts endometritis and elevated pathogen burden. The subject is a female, such as a human female.
Type:
Grant
Filed:
April 16, 2015
Date of Patent:
January 22, 2019
Assignee:
University of Pittsburgh—Of the Commonwealth System of Higher Education
Inventors:
Catherine O'Connell, Toni Darville, Xiaojing Zheng
Abstract: The present invention provides a marker used for detecting colon cancer, and also provides application of said marker in the detection of colon cancer, as well as an associated kit and detection method.
Abstract: An isoform-level gene panel is disclosed that can accurately classify a glioblastoma subtype from a tumor sample. Such an isoform level gene panel comprises the 121 to 214 target isoforms identified in Table 1. Also disclosed are reagents for quantitatively detecting the expression or activity of the target isoforms of Table 1 in a patient sample. For example, such ligands can be PCR primer and probes sets. This isoform-level gene panel and reagents for detection of the isoforms are useful in an isoform-level assay for diagnosis of the molecular subtype of a glioblastoma in a patient. The assay employs algorithms and a novel computer program that performs the functions of FIG. 8. In one aspect, the assay is a high-throughput format.
Type:
Grant
Filed:
April 4, 2014
Date of Patent:
October 30, 2018
Assignees:
The Wistar Institute of Anatomy and Biology, The Trustees of the University of Pennsylvania
Inventors:
Ramana V. Davuluri, Sharmistha Pal, Yingtao Bi, Louise C. Showe, Donald M. O'Rourke, Luke Macyszyn
Abstract: The present invention provides multiplex assays, methods and kits that may be used to detect and confirm the presence of MRSA in a sample. The methods include real-time PCR assays, and the kits and compositions include oligonucleotides used as primers and probes. The present invention further comprises assays useful to identify and differentiate MRSA, MSSA, MRSE, MSSE, MRCNS and MSCNS in a sample.
Type:
Grant
Filed:
March 18, 2011
Date of Patent:
October 16, 2018
Assignees:
The Translational Genomics Research Institute, Arizona Board of Regents on behalf of Northern Arizona University
Inventors:
Elizabeth Driebe, David Engelthaler, Jolene Bowers, Paul Keim
Abstract: Disclosed are: a nucleotide sequence and an amino acid sequence for CDR3 region of T-cell receptor (TCR) gene of WT1-specific cytotoxic T-cell (CTL) for WT1 protein; a method for the detection or treatment of cancer using the nucleotide sequence or the amino acid sequence; and a chip, a primer set, a kit, an apparatus and the like for use in the detection of cancer, each of which comprises the nucleotide sequence or the amino acid sequence.
Type:
Grant
Filed:
February 28, 2008
Date of Patent:
October 9, 2018
Assignee:
International Institute of Cancer Immunology, Inc.
Abstract: The invention encompasses methods and kits used to detect biomarkers that may be used to predict disease outcome in adrenocortical carcinoma patients.
Type:
Grant
Filed:
April 18, 2017
Date of Patent:
September 4, 2018
Assignee:
The Translational Genomics Research Institute
Abstract: The present invention relates to a method for predicting the non-response or response to a monoaminergic antidepressant of a patient to be treated with a monoaminergic antidepressant comprising the steps: (i) determining the DNA-methylation status of a brain-derived neurotrophic factor (BDNF)-gene promoter in a sample of said patient; (ii) attributing a hypomethylation of said BDNF-gene promoter to the non-response to a monoaminergic antidepressant of said patient; and (iii) attributing normal methylation or hypermethylation of said BDNF-gene promoter to the response to a monoaminergic antidepressant of said patient. Furthermore, a kit and the use of a kit in said method is disclosed.
Type:
Grant
Filed:
May 8, 2013
Date of Patent:
August 28, 2018
Assignees:
Medizineische Hochschule Hannover, Universitätsmedizin der Johannes-Gutenberg-Universität Mainz
Inventors:
Helge Frieling, André Tadic, Stefan Bleich, Klaus J. Lieb
Abstract: Recurrent gene fusions in prostate cancer of androgen regulated genes or housekeeping genes and ETS family member genes are described. Compositions and methods having utility in prostate cancer diagnosis, research, and therapy are also provided.
Type:
Grant
Filed:
July 6, 2007
Date of Patent:
August 7, 2018
Assignee:
The Regents of the University of Michigan
Abstract: Disclosed is a method for determining the presence of Mycobacterium tuberculosis complex nucleic acids in a test sample. In particular, regions of the IS6110 preferential locus (ipl) 3?-flanking region of the Mycobacterium tuberculosis complex genome are amplified and detected. In addition, oligonucleotides that can be used as primers to amplify the ipl 3?-flanking region and probe oligonucleotides are described.
Abstract: An in vitro method for predicting the onset of type 1 diabetes (T1D) in a subject, comprises the steps of: (a) measuring the concentration of at least one amino acid, amino acid derivative or amino acid metabolite in a biological sample taken from the subject; (b) determining the subject's HLA genotype; (c) assigning the subject's genetic risk of developing T1D on the basis of the subject's HLA genotype; (d) combining the information obtained in step (a) with the information in step (c); and (e) predicting the likelihood of onset of T1D based upon the combination of step (d). The diagnostic method can be used to select target subjects for T1D prophylactic treatment, and as part of a T1D preventative treatment regime for neonates having a likelihood of developing childhood T1D.
Abstract: Provided are methods and nucleic acids for detecting, differentiating or distinguishing between colon cell proliferative disorders by analysis of one or more of the genes Versican, TPEF, H-Cadherin, Calcitonin, and EYA4. Further provided are novel nucleic acid sequences useful for the cell proliferative disorder specific analysis of said genes as well as methods, assays and kits thereof.
Type:
Grant
Filed:
June 4, 2010
Date of Patent:
June 5, 2018
Assignee:
EPIGENOMICS AG
Inventors:
Peter Adorjan, Matthias Burger, Sabine Maier, Ralf Lesche, Susan Cottrell, Suzanne Mooney
Abstract: Described herein are compositions and methods for the prediction of the prognosis of ovarian cancer subjects. The present invention further provides methods for distinguishing between histological subtypes of ovarian cancer tumors, and also methods and compositions for the treatment or prevention of ovarian cancer. Specifically the invention relates to microRNA molecules associated with said methods and compositions, as well as various nucleic acid molecules relating thereto or derived therefrom.
Type:
Grant
Filed:
November 29, 2016
Date of Patent:
June 5, 2018
Assignees:
ROSETTA GENOMICS LTD., MOR RESEARCH APPLICATIONS
Abstract: Recurrent gene fusions in prostate cancer of androgen regulated genes or housekeeping genes and ETS family member genes are described. Compositions and methods having utility in prostate cancer diagnosis, research, and therapy are also provided.
Type:
Grant
Filed:
November 18, 2008
Date of Patent:
May 1, 2018
Assignee:
THE REGENTS OF THE UNIVERSITY OF MICHIGAN
Inventors:
Arul M. Chinnaiyan, Bo Han, Chandan Kumar
Abstract: The present invention relates to novel methods for the prevention, treatment and diagnosis of Alzheimer's disease. In addition, the invention relates to methods for assessing an individual's susceptibility or pre-disposition to Alzheimer's disease. The methods of the present invention involve the use of therapeutic targets and diagnostic and/or predictive markers within the mTOR signalling pathway. The methods also involve screening subjects for genetic polymorphisms associated with rapamycin-sensitive genes.
Abstract: A category of ?PNA miniprobes and chimeric ?PNA probes is especially useful for detecting RNA and telomeric DNA in a cell sample. In particular, the probes can be used to deliver fluorescent dyes to the telomeres, allowing direct visualization of telomeres in cells.
Type:
Grant
Filed:
November 14, 2012
Date of Patent:
March 27, 2018
Assignees:
CARNEGIE MELLON UNIVERSITY, UNIVERSITY OF PITTSBURGH—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
Inventors:
Bruce A. Armitage, Patricia L. Opresko, Danith Ly, Nathaniel Shank
Abstract: The present invention relates to compositions and methods for cancer diagnosis, research and therapy, including but not limited to, cancer markers. In particular, the present invention relates to recurrent gene fusions as diagnostic markers and clinical targets for prostate cancer.
Type:
Grant
Filed:
June 11, 2014
Date of Patent:
March 27, 2018
Assignee:
THE REGENTS OF THE UNIVERSITY OF MICHIGAN
Abstract: The present invention provides a method, a kit and composition for determining MRSA and other Staphylococcus strain resistance to one or more antibiotic agents through detecting the presence of the respective antibiotic resistance gene. The methods include real-time PCR assays, and the kits and compositions include oligonucleotides used as primers and probes.
Type:
Grant
Filed:
March 18, 2011
Date of Patent:
March 13, 2018
Assignees:
The Translational Genomics Research Institute, Arizona Board of Regents on Behalf of Northern Arizona University
Inventors:
Elizabeth Driebe, David Engelthaler, Jolene Bowers, Paul Keim
Abstract: In one embodiment, the present invention pertains to the use of anoctamin as a biomarker for determining radiation dosimetery. In certain embodiments, the present invention relates to the use of anoctamin as a biomarker for diagnosing the presence of radiation toxicity in a subject who has been exposed to ionizing radiation, as well as for determining the absorbed radiation dose in a subject who has been exposed to a known or unknown dose of ionizing radiation. In another embodiment, the expression level of anoctamin can be used as a secondary endpoint to determine mechanisms of action and/or pharmacodynamic (PD) effects of an agent for reducing radiation toxicity.
Type:
Grant
Filed:
October 7, 2013
Date of Patent:
November 28, 2017
Assignee:
University of Florida Research Foundation, Incorporated